The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

Study Results Support the use of TellDx to Personalize Cancer Care Management –-- Clinical study published in Cancer Discovery --ANDOVER, ...

LEXINGTON The University of Kentucky Markey Cancer Center has treated the first patient in the U.S. with a new immunotherapy ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — ...

In what could be a “game changer” someday for Kentuckians with small cell lung cancer, the University of Markey Cancer Center ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical study.

Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this study targets drug resistance.

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...